Ticker LaunchReverse merger · Completed · CMMB
Chemomab Ltd.
Reverse merger with Anchiano Therapeutics Ltd. (ANCN)
Chemomab Ltd. merged into Anchiano Therapeutics Ltd. (ANCN), a Nasdaq-listed preclinical biopharmaceutical company, in a reverse merger that takes the private company public. The deal was announced on Dec 15, 2020 and closed on Mar 16, 2021. The combined company trades as Chemomab Therapeutics Ltd. (CMMB) on Nasdaq.
Chemomab Therapeutics is a clinical-stage biotech developing CM-101, a first-in-class anti-CCL24 antibody for fibrosis-related diseases, with Phase 2 trials planned in rare fibrotic conditions. It became public by merging with Anchiano Therapeutics.
- Status
- Completed
- Private company
- Chemomab Ltd.
- Public company
- Anchiano Therapeutics Ltd. (ANCN)
- Public company business before
- Nasdaq-listed preclinical biopharmaceutical company
- Announced
- Dec 15, 2020
- Closed
- Mar 16, 2021
- Combined company
- Chemomab Therapeutics Ltd. (CMMB)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Concurrent financing and investors
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
Other completed reverse mergers
- StemoniX, Inc.into Cancer Genetics, Inc. · Mar 30, 2021
- Brooklyn ImmunoTherapeutics LLCinto NTN Buzztime, Inc. · Mar 25, 2021
- Envirotech Drive Systems, Inc.into ADOMANI, Inc. · Mar 16, 2021
- Cosmos Capital Limitedinto Wize Pharma, Inc. · Mar 9, 2021
- Medical Outcomes Research Analytics, LLCinto Helix Technologies, Inc. · Mar 2, 2021
- Riley Exploration - Permian, LLCinto Tengasco, Inc. · Feb 26, 2021